Biological agents targeting the inflammatory components of atherosclerosis aim to mitigate disease progression by blocking specific inflammatory pathways.6 Canakinumab, an IL-1β inhibitor, interrupts the inflammatory cascade and may enhance plaque stability.4 Tocilizumab, which blocks the IL-6 receptor, reduces inflammatory processes and improves endothelial function.6 TNF-α inhibitors (eg, adalimumab, infliximab) suppress vascular wall inflammation by reducing monocyte and macrophage activation.1 This evidence concerns the gene IL1B and atherosclerosis.